Alternative Complement Pathway Inhibition With Iptacopan for the Treatment of C3 Glomerulopathy - Study Design of the APPEAR-C3G Trial

Methods and cohort
- APPEAR-C3G Trial
  - RCT, double blinded
  - Phase III
  - (NCT04817618)
- 38 centers
- 18 countries
- n = 68

Criteria
- Biopsy proven C3G
- Low C3 levels (<77 mg/dl)
- Proteinuria (≥1.0 g/g)
- eGFR ≥30 mL/min/1.73m²

Intervention
- Randomization
  - Placebo vs Iptacopan (1:1)
  - 6 months
- Open label
  - All on Iptacopan

Objectives (Iptacopan vs placebo at 6 months)

Primary
- To demonstrate superiority of iptacopan on proteinuria (UPCR) reduction

Secondary
- Improvement of baseline eGFR
- Effect on patient reported fatigue
- Reduction of glomerular inflammation
- Evaluate safety and tolerability

Conclusion
This study aims to demonstrate the clinical benefits of alternative pathway inhibition with iptacopan in C3 glomerulopathy.

Visual abstract by: Krithika Mohan, MD, DNB
@krithicism

Visual abstract supported by Novartis